Regenerative Medicine “From Science Fiction to Reality: the Rise of Regenerative Medicine”
Main Article Content
Abstract
Regenerative medicine, what was once thought to be science fiction back in the day is now growing to become the most significant advancements made in the field of medicine and clinical studies. Regenerative medicines are medicines that help in repairing and replacing damaged tissue and re-establish organ function impaired by disease, trauma, or congenital abnormalities. Stem cells play a key role in the advancements of regenerative medicine. Stem cells are undifferentiated, meaning they don’t have a specific function and structure like skin cells or muscle cells. But they do have the potential to develop into various specialized cells. They have the ability to regenerate and replace damaged tissue and organs in our body. For example, the lining of the intestines is replaced every four days by the stem cells present beneath it [1]. Stem cells are essential for understanding how the body works and for the development of new therapies for diseases [2].
Regenerative Medicine (RM) overcomes limitations of conventional therapies in settings like myocardial infarction, vascular disease, limb loss, and organ failure by harnessing innate repair mechanisms. Studies in zebrafish—a model capable of regenerating hearts, fins, retina, and spinal cord—reveal key processes: cardiomyocyte dedifferentiation, proliferation, and pathways such as Notch, Wnt, FGF, BMP, and microRNAs [17], [19]. Translating these insights, RM approaches now include bioengineered scaffolds, decellularized extracellular matrices, stem cell transplantation, miRNA modulation, nanomedicine-based treatments, and the creation of 3D organoids [7]. A recent milestone: vascularized cardiac and liver organoids developed by Stanford using patterned growth-factor protocols replicate embryonic vasculature and beat like early hearts—offering scalable disease models and future transplant prospects [8]. Continued exploration in vertebrate models will build an understanding of genetic, epigenetic, and mechanobiological cues—essential for harnessing regeneration in human tissues and organs, promising transformative therapies for life-threatening conditions [1], [19].
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Mason, C., & Dunnill, P. (2008). A brief definition of regenerative medicine. Regenerative Medicine, 3(1), 1–5.
II. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663–676.
III. Voltarelli, J. C., Couri, C. E. B., Stracieri, A. B. P. L., Oliveira, M. C., Moraes, D. A., Pieroni, F., Coutinho, M., Malmegrim, K. C. R., Foss-Freitas, M. C., Simões, B. P., & others. (2007). Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA, 297(14), 1568–1576.
IV. Couri, C. E. B., Oliveira, M. C., Stracieri, A. B. P. L., Moraes, D. A., Pieroni, F., Coutinho, M., & Voltarelli, J. C. (2009). C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in type 1 diabetes. JAMA, 301(15), 1573–1574.
V. Kim, Y., Kim, H., Ko, S., & Park, S. (2016). Three-dimensional beta-cell spheroids derived from human pluripotent stem cells for transplantation therapy. Scientific Reports, 6, Article 35245.
VI. Wang, Y., Wang, L., Zhu, Y., Qin, J., & Zhang, C. (2017). Generation of functional islet organoids from human embryonic stem cells in biomimetic 3D scaffolds. Cell Proliferation, 50(6), e12388.
VII. Shapiro, A. M. J., Pokrywczynska, M., & Ricordi, C. (2017). Clinical pancreatic islet transplantation. Nature Reviews Endocrinology, 13(5), 268–277.
VIII. Sander, M., & Lickert, H. (2022). Engineering vascularized stem-cell derived islets for diabetes therapy. Nature Reviews Endocrinology, 18(9), 549–562.
IX. Zhao, T., Zhang, Z. N., Rong, Z., & Xu, Y. (2011). Immunogenicity of induced pluripotent stem cells. Nature, 474(7350), 212–215.
X. Zhang, Y., Wang, Q., Liu, M., & Yang, L. (2019). Hematopoietic stem cell transplantation for autoimmune diseases: Systematic review and meta-analysis. Autoimmunity Reviews, 18(2), 209–222.
XI. Zhang, L., Liu, Z., & Zhang, W. (2022). Clinical efficacy and safety of hematopoietic stem cell transplantation for type 1 diabetes: Systematic review and meta-analysis. Diabetes Therapy, 13(5), 1033–1047.
XII. Pagliuca, F. W., Millman, J. R., Gürtler, M., Segel, M., Van Dervort, A., Ryu, J. H., ... & Melton, D. A. (2014). Generation of functional human pancreatic β cells in vitro. Cell, 159(2), 428–439.
XIII. Rezania, A., Bruin, J. E., Arora, P., Rubin, A., Batushansky, I., Asadi, A., ... & Kieffer, T. J. (2014). Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nature Biotechnology, 32(11), 1121–1133.
XIV. Vegas, A. J., Veiseh, O., Gürtler, M., Millman, J. R., Pagliuca, F. W., Bader, A. R., ... & Langer, R. (2016). Long-term glycemic control using polymer-encapsulated human stem-cell–derived beta cells in immune-competent mice. Nature Medicine, 22(3), 306–311.
XV. Pepper, A. R., Gala-Lopez, B., Ziff, O., & Shapiro, A. M. J. (2015). Revascularization of transplanted pancreatic islets and role of the transplantation site. Clinical Developmental Immunology, 2013, Article 352315.
XVI. Shapiro, A. M. J., & Lakey, J. R. T. (2001). Clinical islet transplantation. New England Journal of Medicine, 344(13), 889–892.
XVII. Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014). Type 1 diabetes. Lancet, 383(9911), 69–82.
XVIII. Millman, J. R., Xie, C., Van Dervort, A., Gürtler, M., Pagliuca, F. W., & Melton, D. A. (2016). Generation of stem cell-derived β-cells from patients with type 1 diabetes. Nature Communications, 7, Article 11463.
XIX. Kulkarni, R. N., Stewart, A. F., & Klein, D. (2021). Regenerating pancreatic beta cells: Lessons from development, regeneration, and reprogramming. Diabetes, 70(1), 12–23.
XX. D’Amour, K. A., Bang, A. G., Eliazer, S., Kelly, O. G., Agulnick, A. D., Smart, N. G., ... & Baetge, E. E. (2006). Production of pancreatic hormone–expressing endocrine cells from human embryonic stem cells. Nature Biotechnology, 24(11), 1392–1401.